Published on 30 May 2024 on Benzinga
The recently launched Roundhill GLP-1 & Weight Loss ETF OZEM is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO. These two companies are at the forefront of the burgeoning weight-loss drug market, making up over 40% of OZEM’s portfolio.
This ETF presents a unique opportunity for investors to gain exposure to the weight-loss sector through these dominant players.